BRIEF-Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old

Reuters
21 Dec 2024
BRIEF-Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old

Dec 20 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:

  • RHYTHM PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF IMCIVREE® (SETMELANOTIDE) FOR PATIENTS AS YOUNG AS 2 YEARS OLD

Source text: ID:nGNX5BYjf0

Further company coverage: RYTM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10